

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (previously presented) A method for treating a cerebral vascular disease in a human or non-human animal wherein the cerebral vascular disease is selected from the group consisting of occlusive stroke, hemorrhagic stroke, cerebrovasospasm associated with hemorrhagic stroke, and accumulation of blood in subarachnoid space caused by head injury, the method comprising the step of:

administering into the human or non-human animal an inhibitor of a 20-HETE synthesizing enzyme selected from the group consisting of a cytochrome P450 4A (CYP4A) enzyme and a cytochrome P450 4F (CYP4F) enzyme in an amount sufficient to increase or prevent a decrease in cerebral blood flow in the human or non-human animal.

2-6. (canceled)

7. (previously presented) The method of Claim 1, wherein the inhibitor is N-hydroxy-N-(4-butyl-2-methylphenyl)-formamidine (HET0016).

8. (previously presented) The method of Claim 7, wherein HET0016 is administered at a dose sufficient to achieve a blood concentration of about 1 nM to about 1,000 nM.

9. (previously presented) The method of Claim 7, wherein HET0016 is administered at a dose sufficient to achieve a blood concentration of about 2 nM to about 25 nM.

10. (original) The method of Claim 7, wherein HET0016 is administered intravenously.

11. (previously presented) The method of Claim 10, wherein HET0016 is administered at a dose between about 0.003 mg/kg body weight and about 10 mg/kg body weight.

12-14. (canceled)

15. (previously presented) The method of Claim 39, wherein the inhibitor is administered intravenously.

16. (canceled)

17. (previously presented) The method of Claim 39, wherein the 20-HETE synthesizing enzyme inhibitor is administered into cerebrospinal fluid intrathecally via a subdural or intracerebroventricular injection.

18-36. (canceled)

37. (previously presented) The method of Claim 1, wherein the cerebral vascular disease is selected from the group consisting of occlusive stroke and hemorrhagic stroke.

38. (previously presented) The method of Claim 1, wherein the 20-HETE synthesizing enzyme is human cytochrome P450 4A11 (CYP4A11).

39. (previously presented) The method of claim 1, wherein the inhibitor is administered intravenously, to a brain hemorrhage site, or to cerebrospinal fluid.

40. (previously presented) The method of Claim 1, wherein the method is used to treat a cerebral vascular disease in a human.

41. (previously presented) The method of Claim 1, wherein the method is used to treat a cerebral vascular disease in a rat.

42. (previously presented) The method of claim 1, wherein the method is for treating a cerebral vascular disease in a human subject and the inhibitor administered is an inhibitor of human cytochrome P450 4A11 (CYP4A11).

43. (previously presented) The method of claim 42, wherein the inhibitor is administered intravenously, to a brain hemorrhage site, or to cerebrospinal fluid.

44. (previously presented) The method of claim 42, wherein the inhibitor is N-hydroxy-N-(4-butyl-2-methylphenyl)-formamidine (HET0016).